Antagonistic effects of finerenone and spironolactone on the aldosterone‐regulated transcriptome of human kidney cells
Open Access
- 8 January 2021
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 35 (2), e21314
- https://doi.org/10.1096/fj.202002043rr
Abstract
Aldosterone, the main mineralocorticoid hormone in humans, plays a pivotal role in the control of water and salt reabsorption via activation of the mineralocorticoid receptor (MR). Alterations in MR signaling pathway lead to renal dysfunction, including chronic kidney disease and renal fibrosis, that can be prevented or treated with mineralocorticoid receptor antagonists (MRAs). Here, we used RNA‐Sequencing to analyze effects of two MRAs, spironolactone and finerenone, on the aldosterone‐induced transcriptome of a human renal cell line stably expressing the MR. Bioinformatics analysis of the data set reveals the identity of hundreds of genes induced or repressed by aldosterone. Their regulation is modulated in a time‐dependent manner and, for the induced genes, depends on the aldosterone‐driven direct binding of the MR onto its genomic targets that we have previously characterized. Although both MRAs block aldosterone‐induced as well as aldosterone‐repressed genes qualitatively similarly, finerenone has a quantitatively more efficient antagonism on some aldosterone‐induced genes. Our data provide the first complete transcriptome for aldosterone on a human renal cell line and identifies pro‐inflammatory markers (IL6, IL11, CCL7, and CXCL8) as aldosterone‐repressed genes.Keywords
Funding Information
- Bayer (P1155.0)
- Institut National de la Santé et de la Recherche Médicale
- Agence Nationale de la Recherche (ANR EPHIMIR 11‐BSV1‐028‐01, ANR TAMIRAH‐16‐CE17‐0014‐01)
- Fundación Alfonso Martín Escudero
This publication has 59 references indexed in Scilit:
- Dual effect of chemokine CCL7/MCP-3 in the development of renal tubulointerstitial fibrosisBiochemical and Biophysical Research Communications, 2013
- Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trialEuropean Heart Journal, 2013
- TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusionsGenome Biology, 2013
- Integrative genomics viewerNature Biotechnology, 2011
- Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiationNature Biotechnology, 2010
- The circadian clock protein Period 1 regulates expression of the renal epithelial sodium channel in miceJCI Insight, 2009
- Immediate Mineralocorticoid Receptor Blockade Improves Myocardial Infarct Healing by Modulation of the Inflammatory ResponseHypertension, 2008
- IL-18 is expressed in the intercalated cell of human kidneyKidney International, 2007
- The Mineralocorticoid Receptor: Insights into its Molecular and (Patho)Physiological BiologyNuclear Receptor Signaling, 2007
- Aldosterone/salt induces renal inflammation and fibrosis in hypertensive ratsKidney International, 2003